Johanna Bendell, MD, Sarah Cannon Cancer Institute
Articles
Applying Data to the Real World in Gastric Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Emerging Approaches in HER2+ Gastric Cancers
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
VEGFR TKIs in Gastroesophageal Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Maintenance Therapy in Gastric Cancers
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Adjuvant Treatment in Gastroesophageal Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Looking Toward the Future in Gastroesophageal Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Toxicity Management in Second Line for Gastric Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Clinical Rationale for Antiangiogenics in Gastric Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Predicting Response With Biomarkers in Gastric Cancers
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Applying New Data in the Real-World for GEJ Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
ESMO 2020: Practice-Changing Data in Esophageal Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
First-Line I/O Successful in Gastric Adenocarcinoma
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Treatment Landscape in Gastric Cancers Pre-ESMO 2020
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Frontline Treatment in Metastatic Gastric Cancer
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Optimal Approach Toward Advanced Gastric Cancers in US
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Global Trends in Gastric Cancers
Johanna Bendell, MD, Sarah Cannon Cancer Institute;Daniel V. Catenacci, MD, University of Chicago;Ian Chau, MD, Royal Marsden Hospital;Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center;Ken Kato, MD, PhD, National Cancer Center Hospital East
October 22nd 2020Read More
Latest Updated Articles
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
